News
CSTL
36.27
+1.27%
0.46
Castle Biosciences: Study shows TissueCypher test changed management
TipRanks · 6h ago
Weekly Report: what happened at CSTL last week (0921-0925)?
Weekly Report · 7h ago
Castle Biosciences Announces Publication Of New Study Highlighting Demand For Molecular Testing In Atopic Dermatitis
Benzinga · 3d ago
Roth MKM Keeps Their Buy Rating on Castle Biosciences (CSTL)
TipRanks · 6d ago
Castle Biosciences Announces Opening Of New Laboratory And Office Facility In Scottsdale, Arizona
Benzinga · 6d ago
Castle Biosciences to open new laboratory facility in Scottsdale, Arizona
TipRanks · 6d ago
Castle Biosciences management to meet with BTIG
TipRanks · 09/21 17:20
Weekly Report: what happened at CSTL last week (0914-0918)?
Weekly Report · 09/21 09:45
Castle Biosciences’ TissueCypher shows improvement in Barrett’s esophagus
TipRanks · 09/15 11:11
Weekly Report: what happened at CSTL last week (0907-0911)?
Weekly Report · 09/14 09:48
Castle Biosciences publishes DecisionDx-SCC test result study in JAAD
TipRanks · 09/09 20:35
Weekly Report: what happened at CSTL last week (0831-0904)?
Weekly Report · 09/07 09:44
Weekly Report: what happened at CSTL last week (0824-0828)?
Weekly Report · 08/31 09:49
Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know
NASDAQ · 08/28 16:00
Top Executive Makes Bold Move With Major Castle Biosciences Stock Sale
TipRanks · 08/27 02:02
Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?
NASDAQ · 08/25 13:55
Weekly Report: what happened at CSTL last week (0817-0821)?
Weekly Report · 08/24 09:49
Castle Biosciences Insider Move Signals a Big Shift Behind the Scenes
TipRanks · 08/19 02:07
Weekly Report: what happened at CSTL last week (0810-0814)?
Weekly Report · 08/17 09:50
Weekly Report: what happened at CSTL last week (0803-0807)?
Weekly Report · 08/10 09:47
More
Webull provides a variety of real-time CSTL stock news. You can receive the latest news about Castle Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About CSTL
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).